Remove Innovation Remove Kidney Disease Remove Preserved Ejection Fraction
article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research in Chronic Kidney Disease at ACC.25

DAIC

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

article thumbnail

Bayer to Present New Investigational Heart Failure Data, Continued Portfolio Research

DAIC

25 include Efficacy and safety of finerenone across the spectrum of kidney risk in heart failure with mildly reduced or preserved ejection fraction during the session;"Innovations and Insights in Heart Failure With Preserved Ejection Fraction: Emerging Therapies, Biomarkers and Mechanistic Studies."

article thumbnail

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC) 

Cardiometabolic Health Congress

Attendees, including hundreds of health professionals, gained access to the latest knowledge and developments in the field, from exclusive insights from one of the foremost authorities on atherosclerosis, Dr. Peter Libby, to innovations like new therapeutic agents and exciting advancements in renal protection. In the U.S.,

CME 103